Two years after molecular diagnosis of familial hypercholesterolemia: Majority on cholesterol-lowering treatment but a minority reaches treatment goal

PLoS ONE

Volumn 5, Issue 2, 2010, Pages

  Huijgen, Roeland ^a   Kindt, Iris ^b   Verhoeven, Sjoerd B J ^a   Sijbrands, Eric J G ^c   Vissers, Maud N ^a   Kastelein, John J P ^a   Hutten, Barbara A ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b Foundation for the Identification of Persons with Inherited Hypercholesterolemia   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; TRIACYLGLYCEROL;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DRUG POTENCY; DRUG UTILIZATION; DRUG WITHDRAWAL; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; FOLLOW UP; GENE MUTATION; GENETIC SCREENING; HUMAN; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; OUTCOME ASSESSMENT; PREDICTOR VARIABLE; QUESTIONNAIRE; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; ADOLESCENT; AGED; BLOOD; GENETICS; HYPERLIPOPROTEINEMIA TYPE 2; METHODOLOGY; MIDDLE AGED; MUTATION; STATISTICS; TIME;

ADOLESCENT; ADULT; AGED; ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEINS B; CHOLESTEROL, LDL; FOLLOW-UP STUDIES; GENETIC TESTING; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; MIDDLE AGED; MUTATION; NETHERLANDS; OUTCOME ASSESSMENT (HEALTH CARE); QUESTIONNAIRES; RECEPTORS, LDL; TIME FACTORS; YOUNG ADULT;

EID: 77950174523     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0009220     Document Type: Article

References (26)

1. Slack J (1969) Risks of ischaemic heart-disease in familial hyperlipoproteinaemic states. Lancet 2: 1380-1382.
2. Huijgen R, Vissers MN, Defesche JC, Lansberg PJ, Kastelein JJ, et al. (2008) Familial hypercholesterolemia: current treatment and advances in management. Expert Rev Cardiovasc Ther 6: 567-581.
3. Versmissen J, Oosterveer DM, Yazdanpanah M, Defesche JC, Basart DC, et al. (2008) Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ 337: a2423.
4. Neil HA, Hammond T, Huxley R, Matthews DR, Humphries SE (2000) Extent of underdiagnosis of familial hypercholesterolaemia in routine practice: prospective registry study. BMJ 321: 148.
5. Umans-Eckenhausen MA, Defesche JC, Sijbrands EJ, Scheerder RL, Kastelein JJ (2001) Review of first 5 years of screening for familial hypercholesterolaemia in the Netherlands. Lancet 357: 165-168.
6. Umans-Eckenhausen MA, Defesche JC, van Dam MJ, Kastelein JJ (2003) Longterm compliance with lipid-lowering medication after genetic screening for familial hypercholesterolemia. Arch Intern Med 163: 65-68.
7. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, et al. (2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366: 1267-1278.
8. Robinson JG, Smith B, Maheshwari N, Schrott H (2005) Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis. J Am Coll Cardiol 46: 1855-1862.
9. Josan K, Majumdar SR, McAlister FA (2008) The efficacy and safety of intensive statin therapy: a meta-analysis of randomized trials. CMAJ 178: 576-584.
10. Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJ, et al. (2001) Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 357: 577-581.
11. Wierzbicki AS, Humphries SE, Minhas R (2008) Familial hypercholesterolaemia: summary of NICE guidance. BMJ 337: a1095.
12. Walma EP, Visseren FL, Jukema JW, Kastelein JJ, Hoes AW, et al. (2006) The practice guideline 'iagnosis and treatment of familial hypercholesterolaemia'of the Dutch Health Care Insurance Board. Ned Tijdschr Geneeskd 150: 18-23.
13. Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, et al. (2008) Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 358: 1431-1443.
14. Gotto AM Jr, Bierman EL, Connor WE, Ford CH, Frantz ID Jr, et al. (1984) Recommendations for treatment of hyperlipidemia in adults. A joint statement of the Nutrition Committee and the Council on Arteriocslerosis. Circulation 69: 1065A-1090A.
15. Fouchier SW, Kastelein JJ, Defesche JC (2005) Update of the molecular basis of familial hypercholesterolemia in The Netherlands. Hum Mutat 26: 550-556.
16. Umans-Eckenhausen MA, Sijbrands EJ, Kastelein JJ, Defesche JC (2002) Lowdensity lipoprotein receptor gene mutations and cardiovascular risk in a large genetic cascade screening population. Circulation 106: 3031-3036.
17. Leren TP, Finborud TH, Manshaus TE, Ose L, Berge KE (2008) Diagnosis of familial hypercholesterolemia in general practice using clinical diagnostic criteria or genetic testing as part of cascade genetic screening. Community Genet 11: 26-35.
18. Hadfield SG, Horara S, Starr BJ, Yazdgerdi S, Bhatnagar D, et al. (2008) Are patients with familial hypercholesterolaemia well managed in lipid clinics? An audit of eleven clinics from the Department of Health Familial Hypercholesterolaemia Cascade Testing project. Ann Clin Biochem 45: 199-205.
19. Pijlman AH, Huijgen R, Verhagen SN, Imholz BP, Liem AH, et al. (2009) Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands. Atherosclerosis. In press.
20. Souverein OW, Defesche JC, Zwinderman AH, Kastelein JJ, Tanck MW (2007) Influence of LDL-receptor mutation type on age at first cardiovascular event in patients with familial hypercholesterolaemia. Eur Heart J 28: 299-304.
21. Neil HA, Seagroatt V, Betteridge DJ, Cooper MP, Durrington PN, et al. (2004) Established and emerging coronary risk factors in patients with heterozygous familial hypercholesterolaemia. Heart 90: 1431-1437.
22. Fouchier SW, Defesche JC, Kastelein JJ, Sijbrands EJ (2004) Familial defective apolipoprotein B versus familial hypercholesterolemia: an assessment of risk. Semin Vasc Med 4: 259-264.
23. Huijgen R, Kindt I, Fouchier SW, Defesche JC, Hutten BA, et al. (2009) Nonfunctionality of three LDL-R and APOB gene mutations that were assumed to cause familial hypercholesterolemia. Atherosclerosis Supplement 2009 10: P841.
24. Abifadel M, Rabes JP, Jambart S, Halaby G, Gannage-Yared MH, et al. (2009) The molecular basis of familial hypercholesterolemia in Lebanon: Spectrum of LDLR mutations and role of PCSK9 as a modifier gene. Hum Mutat 30: E682-691.
25. Fouchier SW, Huijgen R, Vis K, Defesche JC, Kastelein JJ (2009) Identification of APOB and PCSK9 mutations causing a non-autosomal dominant hypercholesterolemia (ADH) phenotype in molecular diagnosed ADH patients. Atherosclerosis Supplement 2009 10: P870.
26. van der Graaf A, Fouchier SW, Vissers MN, Defesche JC, Wiegman A, et al. (2008) Familial defective apolipoprotein B and familial hypobetalipoproteinemia in one family: two neutralizing mutations. Ann Intern Med 148: 712-714.